@article{BrunaA2016,
title = {A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds},
author = {Bruna, Alejandra
Rueda, Oscar M.
Greenwood, Wendy
Batra, Ankita Sati
Callari, Maurizio
Batra, Rajbir Nath
Pogrebniak, Katherine
Sandoval, Jose
Cassidy, John W.
Tufegdzic-Vidakovic, Ana
Sammut, Stephen-John
Jones, Linda
Provenzano, Elena
Baird, Richard
Eirew, Peter
Hadfield, James
Eldridge, Matthew
McLaren-Douglas, Anne
Barthorpe, Andrew
Lightfoot, Howard
O'Connor, Mark J.
Gray, Joe
Cortes, Javier
Baselga, Jose
Marangoni, Elisabetta
Welm, Alana L.
Aparicio, Samuel
Serra, Violeta
Garnett, Mathew J.
Caldas, Carlos},
url = {https://www.ncbi.nlm.nih.gov/pubmed/27641504},
year = {2016},
date = {2016-09-22},
journal = {Cell},
abstract = {The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform combining invivo maintenance of these PDTXs along with short-term cultures of PDTX-derived tumor cells (PDTCs) was optimized. Remarkably, the intra-tumor genomic clonal architecture present in the originating breast cancers was mostly preserved upon serial passaging in xenografts and in short-term cultured PDTCs. We assessed drug responses in PDTCs on a high-throughput platform and validated several exvivo responses invivo. The biobank represents a powerful resource for pre-clinical breast cancer pharmacogenomic studies (http://caldaslab.cruk.cam.ac.uk/bcape), including identification of biomarkers of response or resistance. Copyright 2016 The Authors. Published by Elsevier Inc. All rights reserved.},
keywords = {breast cancer, explants, intra-tumor heterogeneity},
pubstate = {published},
tppubtype = {article}
}